Vicore Pharma Holding AB (VCRE) Stock Analysis

AI analysis of Vicore Pharma Holding AB (VCRE)

Buy

Vicore Pharma (VCRE) is a good buy right now due to its favorable technical indicators and positive analyst outlook. The current price is $9.59, significantly below the analyst price target of $25, indicating a potential upside of over 160%. Additionally, the stock has shown a recent 5-day change of +2.02%, suggesting a positive momentum. However, the main risk is the negative net income trend, with a net income loss of -142,844,000 SEK in Q2 2026, which highlights ongoing financial challenges.

Valuation Metrics

The current forward P/E ratio for Vicore Pharma Holding AB (VCRE) is 0.00, compared to its 5-year average forward P/E of .

Forward P/E

5Y Average P/E

Current P/E

0.00

Forward EV/EBITDA

5Y Average EV/EBITDA

Current EV/EBITDA

0.00

Forward P/S

Fair

5Y Average P/S

13.42

Current P/S

5.78

Overvalued

36.44

Undervalued

-9.61

VCRE FAQ — answered by Alphio AI

Vicore Pharma Holding AB is a Sweden-based drug-development company. The Company's portfolio contains small molecules with potential indications, including anti-inflammation, nerve generation and cardiovascular disease. The Company is a wholly owned subsidiary of Mintage Scientific AB. It operates in the Healthcare sector.

Vicore Pharma (VCRE) is a good buy right now due to its favorable technical indicators and positive analyst outlook. The current price is $9.59, significantly below the analyst price target of $25, indicating a potential upside of over 160%. Additionally, the stock has shown a recent 5-day change of +2.02%, suggesting a positive momentum. However, the main risk is the negative net income trend, with a net income loss of -142,844,000 SEK in Q2 2026, which highlights ongoing financial challenges.